Similarly, a high TIGIT/DNAM-1 ratio on tumor-infiltrating Tregs was shown to correlate with poor clinical outcomes following ICB targeting PD-1 and/or CTLA-4 [122]. Here, PDCD1 is linked to neoplasm.